Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma

Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma

Abstract Background Malignant peritoneal mesothelioma (MPM) is an extremely rare and highly invasive tumor. Due to the lack of accurate models that reflect the biological characteristics of primary tumors, studying MPM remains challenging and is associated with an exceedingly unfavorable prognosis....

Full description

Bibliographic Details
Main Authors: XiaoChang Fang, Lin Shu, TianLiang Chen, XiaoLe Zhao, LiuCui Yang, Tingting Dou, Lijie Yang, Xuanfei Li, Maohui Feng
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Molecular Cancer
Subjects:
Malignant peritoneal Mesothelioma
Organoids
Patient-derived organoids (PDO)
Primary cell lines
Patient-derived organoids xenograft (PDOX)
Peritoneal orthotopic xenograft
Online Access:https://doi.org/10.1186/s12943-023-01901-z

Internet

https://doi.org/10.1186/s12943-023-01901-z

Similar Items